Skip to content

Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing

NUTRI.AGE: DEVELOPMENT OF SMART FOOD/NUTRACEUTICAL SOLUTIONS DEDICATED TO CARDIOMETABOLIC DISORDERS IN AGEING

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07817290
Acronym
NutriAge
Enrollment
15
Registered
2026-09-14
Start date
2025-06-24
Completion date
2026-11-30
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Keywords

prediabetes, type 2 diabetes, cardiovascular diseases

Brief summary

Describe the anthropometric measurements and informations relating to body composition, blood chemistry tests, blood glucose monitoring, and dietary habits of the volunteers participating in the study before and after taking probiotics.

Detailed description

The clinical research is aimed at exploring the in vivo functionality in humans of ingredients produced and formulated at a pre-competitive pilot level, namely the ability to reduce blood pressure or modify the RAAS (renin-angiotensin-aldosterone system) through the presence of substrates with ACE-inhibitory activity, and/or improve metabolic status through the administration of probiotic strains whose products have a known metabolic effect in in vitro, in vivo animal, or human models (in other subject categories). The use of "enhanced bioactive compounds" (ACE inhibitors, pre-, pro-, and post-biotics) together with selected probiotics in newly formulated food supplements may be strategic in supporting specific diets and pharmacological treatments in older adults with cardiometabolic disorders (CVD). The result of these technological convergences will culminate with the in vivo trial of some nutraceutical-food systems useful for the well-being of the elderly suffering from cardiometabolic pathologies (CVDs).

Interventions

DIETARY_SUPPLEMENTProbiotic

Participants will receive a probiotic for 60 days to allow comparison of the results with those observed in the placebo arm. Participants will take one probiotic capsule once daily in the morning, on an empty stomach.

Sponsors

Azienda Ospedaliero Universitaria Maggiore della Carita
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients of either gender, over 65 years of age, able to understand the protocol procedures. * Known cardiovascular disease * Prediabetes or type 2 diabetes mellitus with HbA1c \< 7.0% on diet alone or metformin.

Exclusion criteria

* Age under 65 * Previous diagnosis of type 2 diabetes mellitus already undergoing drug therapy (except metformin) * Contraindications such as allergy to product components * Obesity secondary to diseases: genetic (Prader-Willi syndrome, Down syndrome); metabolic and endocrine (Cushing's syndrome, hypothyroidism) * Endocrine or liver disease or clinical evidence of chronic disease or gastrointestinal disorders or malabsorption disorders * History of adrenal adenoma or secondary arterial hypertension due to renal/adrenal causes * Arterial hypertension treated with an ACE inhibitor or ARB * Previous bariatric surgery

Design outcomes

Primary

MeasureTime frameDescription
Blood glucose assessment with OGTT test and FGM4 monthsBlood glucose and insulin tests at 0', 30', 60', 90', 120' minutes every 30 minutes Blood glucose monitoring at home
Pressure assessment4 monthsBlood pressure is assessed during the visit at time 0 and after 60 days Filling out a blood pressure diary at home

Secondary

MeasureTime frameDescription
Anthropometric measurementsevaluation of weight and body composition through study completion, an average of 4 monthsWeight is assessed in Kg with the use of the bioimpedance balance.
Adherence level to the Western diet with European Prospective Investigation into Cancer and Nutrition (EPIC) questionnairesevaluation of weight and body composition through study completion, an average of 4 monthsAssessed with the use of questionnaire. EPIC is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
Adherence level to the Western diet with 24h recall questionnairesevaluation of weight and body composition through study completion, an average of 4 monthsAssessed with the use of questionnaires. 24h recall questionnaire is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
Advanced glycation end products quantificationevaluation of weight and body composition through study completion, an average of 4 monthsAGE levels will be measured using skin fluorescence, using the "AGE reader mu" device (range from 1.3 to 5 level of AGEs respect to the patient's age)
Endogenous and exogenous AGEs plasma quantificationevaluation of weight and body composition through study completion, an average of 4 monthsAGEs will also be assessed at the plasma level in free form (ELISA, fluorescence assay) or bound to hemoglobin (HbA1c clinical practice test), both measured in pg/mL
Soluble RAGEs plasma quantificationevaluation of weight and body composition through study completion, an average of 4 monthsRAGEs will also be assessed at the plasma level in solule form (ELISA) measured in pg/mL

Countries

Italy

Contacts

CONTACTFlavia Prodam, MD PhD
flavia.prodam@med.uniupo.it+39-0321-660693
PRINCIPAL_INVESTIGATORFlavia Prodam, MD PhD

AOU Maggiore della Carità

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026